Traws Pharma, Inc. 8-K

What Happened
Traws Pharma, Inc. (TRAW) announced on February 19, 2026 that it completed its analysis of a study of ratutrelvir — a ritonavir-free treatment — in PAXLOVID®-eligible and -ineligible patients with mild-to-moderate COVID-19. The company also provided updates regarding an additional indication for tivoxavir marboxil as a prophylactic treatment for seasonal influenza. The announcements were made via a press release filed as Exhibit 99.1 to the Form 8-K.

Key Details

• Date filed: February 19, 2026 (Form 8-K Item 8.01).
• Drug programs referenced: ratutrelvir (ritonavir-free COVID-19 treatment) and tivoxavir marboxil (update for prophylactic use against seasonal influenza).
• Study population noted: PAXLOVID®-eligible and PAXLOVID®-ineligible patients with mild-to-moderate COVID-19.
• Press release included as Exhibit 99.1 to the 8-K.

Why It Matters
Completion of the ratutrelvir study analysis and the tivoxavir indication update are material operational developments for Traws Pharma’s clinical pipeline. For investors, these updates may affect program timelines, regulatory strategy, and future clinical or commercial decisions. The Form 8-K indicates the company has publicly filed details via a press release; investors should review that release and await follow-up disclosures (e.g., detailed study results, regulatory filings, or guidance) for information that could impact valuation.